The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
April 28th 2024
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on primary progressive aphasia.
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
September 15, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Alzheimer Disease: Separating Fact from Fiction
November 16th 2023In honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.
Mechanistic Potential of Synapse-Targeted Agent ALX-001 for Alzheimer Disease: Adam Mecca, MD, PhD
November 14th 2023The associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine discussed the mechanism of action of ALX-001, a highly selective agent in development for neurodegenerative diseases. [WATCH TIME: 5 minutes]
Differences Between Antiamyloid Therapies Lecanemab and Donanemab: Martin Sadowski, MD, PhD
November 13th 2023The professor of neurology, psychiatry, and pharmacology at the NYU Grossman School of Medicine commented on the differences in mechanisms and clinical trial data between lecanemab and donanemab. [WATCH TIME: 5 minutes]
Fosgonimeton's Impact on Neuroprotection and Cognition in Alzheimer Disease
November 12th 2023Kevin Church, PhD, chief scientific officer at Athira Pharma, discussed preclinical findings of fosgonimeton where the therapy exhibited procognitive effects among mice models in Alzheimer disease, as presented at CTAD 2023.
Overviewing Preliminary Data of ABvac40, a Vaccine for Alzheimer Disease: Jose Terencio, PhD
November 8th 2023The vice president of Innovation and New Technologies at Grifols provided perspective on the interim phase 2 findings of ABvac40, a vaccine in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]
NeuroVoices: Joseph Foss, MD, on NTRX-07 and CBR2-Targeting Therapies for Alzheimer Disease
November 8th 2023The chief medical officer of NeuroTherapia provided insight on promising phase 1b data assessing NTRX-07, a CBR2-targeting agent in development for patients with early-stage Alzheimer disease.
NeuroVoices: David Greeley, MD, on AR1001, an Oral PDE5 Inhibitor for Alzheimer Disease
November 1st 2023David Greeley, MD, chief medical officer at AriBio and study author, provided commentary on the mechanism of action of AR1001, its promising effect on ptau181, and the next steps in its development.
Reviewing the Phase 2 OVERTURE Results of Gamma Sensory Stimulation Device: Brent Vaughan
October 30th 2023The chief executive officer of Cognito Therapeutics detailed clinical findings from the open-label extension of the phase 2 OVERTURE study presented at the recent Clinical Trials on Alzheimer’s Disease conference. [WATCH TIME: 4 minutes]
Clinical Potential of Cognito’s Gamma Sensory Stimulation Device in Alzheimer Disease: Brent Vaughan
October 27th 2023The chief executive officer of Cognito Therapeutics provided an in-depth overview of the company’s gamma sensory stimulation device, its mechanism of action, and why it serves as a promising therapy for patients with Alzheimer disease. [WATCH TIME: 5 minutes]